🔴 Moleculin Biotech is trading 18.27% down in pre-market — no clear company-specific catalyst identified

Moleculin Biotech is trading at $0.30, down 18.27% in pre-market, with no clear company-specific catalyst identified.

• Its latest listed release is an October 7 conference announcement; no October 16 announcement appears on the press-release page.
• An October 16 report discusses reverse-split authority approved October 9, but available evidence does not establish it as the cause.
• Recent closes fell from $0.44 on October 13 to $0.37 on October 15; available market indices were mixed, with no broad same-direction move above 0.5%.